AN Venture Partners, a global biotech venture capital fund, recently invested in Imbria Pharmaceuticals, a clinical stage company based in Cambridge, MA, USA. Imbria is focused on developing novel therapies designed to enhance cellular energy and improve outcomes for patients with cardiometabolic disorders.

Imbria announced positive clinical results from Part 2 of the IMPROVE-DiCE Phase 2 trial, demonstrating that ninerafaxstat improved cardiac energetics, left ventricular reserve capacity, exercise capacity and patient-reported heart failure symptoms and physical limitations in patients with cardiometabolic heart failure with preserved ejection fraction (HFpEF).

The results were presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25) in Chicago, IL during the moderated poster session titled “Innovations and Insights in Heart Failure with Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies.

For the full announcement, please see Imbria’s press release here.

 
About AN Venture Partners

ANV is a Tokyo and San Francisco-based biotech venture capital firm. ANV is dedicated to building high impact global biotech companies and specializes in sourcing scientific opportunities from Japan.

Media Contacts
Email: info@an.vc